COGNITION THERAPEUTICS INC

CGTX - CIK 0001455365

Market cap-

Rank-

SEC filings289

COGNITION THERAPEUTICS INC trades as CGTX. This page tracks COGNITION THERAPEUTICS INC through 289 SEC filings, with financial statements and metrics updated as new reports are filed.

Key metrics

Net income (latest FY)-$23.49MFY 2025

Operating cash flow (latest FY)-$24.59MFY 2025

Total assets (latest FY)$48.39MFY 2025

Financial performance

CGTX annual net incomeView details

CGTX operating cash flowView details

Key statistics

EPS (diluted)FY 2025: $-0.32
Shares outstandingas of 2026-05-05: 0.09B
Total equityas of 2026-03-31: $29.91M
Return on equity: -78.5%
Cash & equivalentsas of 2026-03-31: $31.13M
Current ratioas of 2026-03-31: 5.92
R&D expenseFY 2025: $37.19M

Latest filings

Filing	Type	Filed
Major company event	8-K	2026-05-21
Quarterly report	10-Q	2026-05-08
Major company event	8-K	2026-05-07
Insider trade	4	2026-05-04
Annual report to shareholders	ARS	2026-04-27
Proxy materials	DEFA14A	2026-04-27
Proxy statement	DEF 14A	2026-04-27
Insider trade	4	2026-04-20

Browse the full filing history (289 filings)

Similar companies

The largest companies sharing COGNITION THERAPEUTICS INC's SEC industry classification (biological products, (no diagnostic substances)).

AMGNAmgen Inc.$182.28 B CGTX vs AMGN

GILDGilead Sciences, Inc.$150.83 B CGTX vs GILD

ARGXargenx SE$53.35 B CGTX vs ARGX

RVMDRevolution Medicines, Inc.$30.74 B CGTX vs RVMD

BIIBBiogen Inc.$28.73 B CGTX vs BIIB

Frequently asked questions

Is COGNITION THERAPEUTICS INC profitable?

In its latest fiscal year COGNITION THERAPEUTICS INC reported a net loss of $23.49M.

Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.